MeSH D005879 - tourette syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Clonidine | Clonidine |  | 1986-07-08 |  |  |
| Pimozide | Orap |  | 1984-07-31 |  |  | |
| Pergolide | Pergolide |  | 2003-09-04 |  |  | |
| Risperidone | Uzedy | 2025-01-12 | 2023-04-28 |  |  | |
| Risperidone | Risperidone |  | 2023-12-05 |  |  | |
| Novast Laboratories | Clonidine | Clonidine |  | 2019-03-05 |  |  |
| Taro Pharmaceutical | Risperidone | Risperidone |  | 2011-02-07 |  |  |
| Mylan | Clonidine | Clonidine |  | 2010-07-16 |  |  |
| Clonidine | Duraclon |  | 1996-10-02 |  |  | |
| NATCO Pharma | Clonidine, Chlorthalidone | Clorpres |  | 1987-02-09 |  |  |
| Risperidone | Risperidone |  | 2008-09-15 |  |  | |
| Johnson & Johnson | Risperidone | Risperdal |  | 1993-12-29 | $374 M | Y2022 |
| Chartwell Pharmaceuticals | Clonidine | Clonidine |  | 2017-10-23 |  |  |
| Risperidone | Risperidone |  | 2012-03-12 |  |  | |
| Sandoz | Risperidone | Risperidone |  | 2009-12-22 |  |  |
| Boehringer Ingelheim | Clonidine | Catapres |  | 1982-01-01 |  |  |
| Clonidine, Chlorthalidone | Combipres |  | 1982-01-01 |  |  |
1
2
3
4
5
6
...
9
>
Clinical Trials
Historical Success Rate
Phase 1
38%3/8
Phase 2
17%2/12
Phase 3
80%12/15
Approved: 9Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use